poly I-poly C12U
PreclinicalSmall molecule
poly I-poly C12U is one of 20 small molecule programs targeting Chronic Fatigue Syndrome. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Chronic Fatigue Syndrome
#DrugCompanyPhaseTrials
1Xyrem
Jazz PharmaceuticalsApproved
Sunosi
AAxsome Therapeutics, Inc.
Approved
Rituxan
RochePhase 3
Lisdexamfetamine Dimesylate
TakedaApproved
Cymbalta
Alnylam PharmaceuticalsPhase 2
Northera
LundbeckPhase 2
Kineret
SSwedish Orphan Biovitrum
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Enbrel
IImmunex
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Safety and Efficacy1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for poly I-poly C12U. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAIM ImmunoTech Inc.